1. alelima@usp.br www.patentes.usp.br
DRUGS FOR UTILIZATION ON PREVENTION AND TREATMENT OF DISEASES WITH A HIGH MORTALITY RATE ON BOVINES
CÉLIA REGINA DA SILVA GARCIA; ALEXANDRE BUDU; JULIO CESAR LEVANO GARCIA; LUCAS BORGES PEREIRA; MANEESH KUMAR SINGH; MIRIAM SANTOS DE MORAES.
INTRODUCTION
The economic losses caused by bovine parasites, in Brazil, were estimated on an annual basis of approximately US$ 30 billion, which calls for urgent discovery of new targets for development of drugs for veterinary use. Therefore, the profitability of cattle raising can be increased if the matter of cattle infectivity was resolved.
With that in mind, this technology describes an utilization method of serpentine receptor PfSR25 for a potential parasiticide medication, which can be used, for instance, for the treatment of bovine malaria, among other veterinarian diseases, such as anaplasmosis and neosporosis.
The etiological agent of the disease’s most aggressive form, Plasmodium falciparum, invades red blood cells and resides inside the parasitophorous vacuole, and circumvents through many changes during its development. The parasite is capable of perceiving the environment surrounding it and elaborate proper cellular responses, which concern protein secretion and cellular growth and differentiation. That is why the referred receptor PfSR25 can be useful for potential anti-parasitic treatment, once it is a monovalent cation sensor capable of modulating Ca2+ signaling in the parasites and thus making them more sensible to induced death by anti-malarial drugs, such as chloroquine and piperaquine.
APPLICATION AND TARGET MARKET
The present invention inserts itself in the biotechnology segment, once it is an utilization method of serpentine receptor PfSR25 for a possible therapeutic that can treat malaria among other bovine diseases. Its target markets are biotechnological and biomedical companies, and pharmaceutical and veterinarian industries.
DEVELOPMENT STAGE
Area: Farming; 0083/2017
Institute of Biosciences – USP
SUPPORT AND FOMENTATION: process n 2011/ , Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). “Opinions, hypotheses and conclusions or recommendations expressed in this material are the responsibility of the author(s) and not necessarily reflect the vision of FAPESP.”
Patent protected under the no. BR
São Paulo Pole